49 results
Page 2 of 3
8-K
EX-99.1
n2tlgpw9usyeztzdqim
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
S-3ASR
h2gb2f9m2 70i
23 Sep 22
Automatic shelf registration
4:08pm
8-K
EX-99.1
2whh2u cy6
9 Aug 22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
6:45am
424B5
tj3oa9i pp
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
gnyy8fbe
20 Jul 22
Prospectus supplement for primary offering
4:22pm
8-K
tiv9jhnkj p9e
12 Jul 22
Other Events
7:00am
S-3
34dnb w18113u
1 Jul 22
Shelf registration
4:36pm
8-K
EX-99.1
gzpk gvsn
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
DEF 14A
zszu wsrjdi880y
29 Apr 22
Definitive proxy
7:01am
10-K
lx8aa2br rs6l
14 Mar 22
Annual report
7:04am
8-K
EX-99.1
facofb gtnha5ju82
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
8-K
EX-99.1
19yhu6lyalg icte8xyh
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
10-Q
05ug4rsshn
12 Aug 21
Quarterly report
8:53am
8-K
EX-99.1
16cdz
12 Aug 21
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
8:20am
424B4
pslo320urshn
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
iclp4
14 Jun 21
IPO registration (amended)
6:15am